Schedule 13D ownership disclosure
CONNECT BIOPHARMA HLDGS LTD
Ordinary Shares · CUSIP: 207523101
Event date: 2025-07-21
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Panacea Innovation LimitedReported CIK 0002010692
Shares: 13,950,000 · Class: 25.1%
- Panacea Venture Healthcare Fund II, L.P.Reported CIK 0001869939
Shares: 13,950,000 · Class: 25.1%
- Panacea Venture Healthcare Fund II GP Company, Ltd.
Shares: 13,950,000 · Class: 25.1%
- James HuangReported CIK 0001573160
Shares: 13,950,000 · Class: 25.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-097088
- Form type
- SCHEDULE 13D/A
- Filer
- Connect Biopharma Holdings Ltd
- CIK
- CIK 1835268
- Filed
- Jul 21, 2025
- Reporting period
- Jul 21, 2025
- Description
- Schedule 13D beneficial ownership